DeepMed Research

M.D. ANDERSON CANCER CENTER

🇺🇸United States

Country: 🇺🇸United States

Ownership: -

Employees: -

Market Cap: -

Website

Clinical Trials

ARID1A and/or KDM6A Mutation and CXCL13 Expression

Phase 2

Active, not recruiting

Conditions: Locally Advanced Urothelial Carcinoma
Locally Advanced Ureter Urothelial Carcinoma
Metastatic Renal Pelvis Urothelial Carcinoma
Recurrent Renal Pelvis Urothelial Carcinoma
Recurrent Ureter Urothelial Carcinoma
Stage IIIA Bladder Cancer AJCC v8
Unresectable Ureter Urothelial Carcinoma
Unresectable Urethral Urothelial Carcinoma
Unresectable Urothelial Carcinoma
Locally Advanced Bladder Urothelial Carcinoma

Interventions: Other: Diagnostic Laboratory Biomarker Analysis
Biological: Nivolumab
Drug: Relatlimab

First Posted Date: 2021-07-07

Last Posted Date: 2025-04-09

Lead Sponsor: M.D. Anderson Cancer Center

Target Recruit Count: 6

Registration Number: NCT04953104

Locations: 🇺🇸
M D Anderson Cancer Center, Houston, Texas, United States

Androgen Ablation Therapy with or Without Niraparib After Radiation Therapy for the Treatment of High-Risk Localized or Locally Advanced Prostate Cancer

Phase 2

Recruiting

Conditions: Prostate Carcinoma
Stage IIC Prostate Cancer AJCC V8
Stage III Prostate Cancer AJCC V8
Stage IIIA Prostate Cancer AJCC V8
Stage IIIB Prostate Cancer AJCC V8
Stage IIIC Prostate Cancer AJCC V8
Stage IVA Prostate Cancer AJCC V8

Interventions: Drug: Antiandrogen Therapy
Drug: Abiraterone Acetate
Drug: Apalutamide
Procedure: Biopsy
Radiation: Radiation Therapy
Drug: Niraparib
Drug: Prednisone

First Posted Date: 2021-07-01

Last Posted Date: 2025-02-13

Lead Sponsor: M.D. Anderson Cancer Center

Target Recruit Count: 200

Registration Number: NCT04947254

Locations: 🇺🇸
M D Anderson Cancer Center, Houston, Texas, United States

Gemcitabine, Nab-paclitaxel, Durvalumab, and Oleclumab Before Surgery for the Treatment of in Resectable/Borderline Resectable Primary Pancreatic Cancer

Phase 2

Active, not recruiting

Conditions: Resectable Pancreatic Adenocarcinoma
Stage IB Pancreatic Cancer AJCC v8
Stage IIA Pancreatic Cancer AJCC v8
Stage IIB Pancreatic Cancer AJCC v8
Borderline Resectable Pancreatic Adenocarcinoma
Stage IA Pancreatic Cancer AJCC v8

Interventions: Biological: Durvalumab
Drug: Gemcitabine
Drug: Nab-paclitaxel
Biological: Oleclumab

First Posted Date: 2021-06-25

Last Posted Date: 2025-05-13

Lead Sponsor: M.D. Anderson Cancer Center

Target Recruit Count: 13

Registration Number: NCT04940286

Locations: 🇺🇸
M D Anderson Cancer Center, Houston, Texas, United States

Tocilizumab, Ipilimumab, and Nivolumab for the Treatment of Advanced Melanoma, Non-Small Cell Lung Cancer, or Urothelial Carcinoma

Phase 2

Active, not recruiting

Conditions: Locally Advanced Bladder Urothelial Carcinoma
Locally Advanced Ureter Urothelial Carcinoma
Metastatic Bladder Urothelial Carcinoma
Metastatic Melanoma
Metastatic Renal Pelvis Urothelial Carcinoma
Metastatic Ureter Urothelial Carcinoma
Pathologic Stage IIID Cutaneous Melanoma AJCC v8
Stage III Urethral Cancer AJCC v8
Locally Advanced Bladder Carcinoma
Locally Advanced Renal Pelvis Urothelial Carcinoma

Interventions: Biological: Ipilimumab
Biological: Nivolumab
Biological: Tocilizumab

First Posted Date: 2021-06-25

Last Posted Date: 2024-05-16

Lead Sponsor: M.D. Anderson Cancer Center

Target Recruit Count: 35

Registration Number: NCT04940299

Locations: 🇺🇸
M D Anderson Cancer Center, Houston, Texas, United States

Liposomal Cytarabine, Daunorubicin, and Gemtuzumab Ozogamicin for the Treatment of Relapsed Refractory Pediatric Patients With Acute Myeloid Leukemia

Phase 1

Completed

Conditions: Refractory Acute Myeloid Leukemia
Secondary Acute Myeloid Leukemia
Recurrent Acute Myeloid Leukemia
Acute Myeloid Leukemia Arising From Previous Myelodysplastic Syndrome

Interventions: Drug: Gemtuzumab Ozogamicin
Drug: Liposome-encapsulated Daunorubicin-Cytarabine

First Posted Date: 2021-06-07

Last Posted Date: 2025-04-27

Lead Sponsor: M.D. Anderson Cancer Center

Target Recruit Count: 1

Registration Number: NCT04915612

Locations: 🇺🇸
M D Anderson Cancer Center, Houston, Texas, United States

Predictive Biomarkers for Pneumonitis After Chemoradiotherapy and Immunotherapy in Patients With Non-small Cell Lung Cancer

Recruiting

Conditions: Lung Non-Small Cell Carcinoma

Interventions: Procedure: Biospecimen Collection
Procedure: Bronchoscopy with Bronchoalveolar Lavage
Other: Chemoradiotherapy
Procedure: Computed Tomography
Other: Diagnostic Laboratory Biomarker Analysis
Drug: Immune Checkpoint Inhibitor
Procedure: Nasal Wash and Collection
Other: Quality-of-Life Assessment
Other: Questionnaire Administration
Procedure: Spirometry

First Posted Date: 2021-06-04

Last Posted Date: 2025-02-26

Lead Sponsor: M.D. Anderson Cancer Center

Target Recruit Count: 150

Registration Number: NCT04913311

Locations: 🇺🇸
M D Anderson Cancer Center, Houston, Texas, United States

Effect of Materials for Subcuticular Suture (Quill vs. Monocryl) on Complications After Liver Resection

Recruiting

Conditions: Liver and Intrahepatic Bile Duct Neoplasm

Interventions: Other: Electronic Health Record Review

First Posted Date: 2021-05-28

Last Posted Date: 2023-04-12

Lead Sponsor: M.D. Anderson Cancer Center

Target Recruit Count: 40

Registration Number: NCT04906174

Locations: 🇺🇸
M D Anderson Cancer Center, Houston, Texas, United States

Sitravatinib and Nivolumab for the Treatment of Metastatic or Advanced Clear Cell Renal Cell Cancer

Phase 2

Active, not recruiting

Conditions: Metastatic Clear Cell Renal Cell Carcinoma
Advanced Clear Cell Renal Cell Carcinoma
Stage IV Renal Cell Cancer AJCC v8

Interventions: Biological: Nivolumab
Other: Quality-of-Life Assessment
Other: Questionnaire Administration
Drug: Sitravatinib

First Posted Date: 2021-05-27

Last Posted Date: 2025-06-04

Lead Sponsor: M.D. Anderson Cancer Center

Target Recruit Count: 88

Registration Number: NCT04904302

Locations: 🇺🇸
M D Anderson Cancer Center, Houston, Texas, United States
🇺🇸
Indiana University Hospital / IU Simon Cancer Center, Indianapolis, Indiana, United States

Plinabulin in Combination With Radiation/Immunotherapy in Patients With Select Advanced Cancers After Progression on PD-1 or PD-L1 Targeted Antibodies

Phase 1

Terminated

Conditions: Clinical Stage IV Merkel Cell Carcinoma AJCC v8
Advanced Bladder Carcinoma
Clinical Stage III Cutaneous Melanoma AJCC v8
Pathologic Stage IIIA Cutaneous Melanoma AJCC v8
Pathologic Stage IIID Cutaneous Melanoma AJCC v8
Stage III Lung Cancer AJCC v8
Stage IIIC Lung Cancer AJCC v8
Stage IV Bladder Cancer AJCC v8
Stage IV Lung Cancer AJCC v8
Advanced Lung Non-Small Cell Carcinoma

Interventions: Biological: Atezolizumab
Drug: Avelumab
Biological: Durvalumab
Biological: Nivolumab
Biological: Pembrolizumab
Drug: Plinabulin
Radiation: Radiation Therapy

First Posted Date: 2021-05-26

Last Posted Date: 2025-06-04

Lead Sponsor: M.D. Anderson Cancer Center

Target Recruit Count: 19

Registration Number: NCT04902040

Locations: 🇺🇸
M D Anderson Cancer Center, Houston, Texas, United States

Local Consolidative Therapy and Durvalumab for Oligoprogressive and Polyprogressive Stage III NSCLC After Chemoradiation and Anti-PD-L1 Therapy

Phase 2

Recruiting

Conditions: Stage IIIA Lung Cancer AJCC v8
Stage IIIB Lung Non-Small Cell Cancer AJCC v7
Stage IIIA Lung Non-Small Cell Cancer AJCC v7
Stage IIIB Lung Cancer AJCC v8
Stage III Lung Cancer AJCC v8
Stage III Lung Non-Small Cell Cancer AJCC v7
Stage IIIC Lung Cancer AJCC v8

Interventions: Biological: Durvalumab
Drug: Carboplatin
Procedure: Local Consolidation Therapy
Other: Quality-of-Life Assessment
Drug: Gemcitabine
Other: Questionnaire Administration
Drug: Nab-paclitaxel
Drug: Paclitaxel
Drug: Pemetrexed

First Posted Date: 2021-05-19

Last Posted Date: 2025-02-21

Lead Sponsor: M.D. Anderson Cancer Center

Target Recruit Count: 51

Registration Number: NCT04892953

Locations: 🇺🇸
M D Anderson Cancer Center, Houston, Texas, United States

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy